Efficacy and safety of cilostazol therapy in ischemic stroke: A meta-analysis

Journal of Stroke and Cerebrovascular Diseases

Volumn 24, Issue 5, 2015, Pages 930-938

  Tan, Liang ^a   Margaret, Barnhart ^b   Zhang, John H ^b   Hu, Rong ^a   Yin, Yi ^a   Cao, Liu ^a   Feng, Hua ^a   Zhang, Yanqi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplatelet therapy; Cilostazol hemorrhage; Ischemic stroke; meta analysis

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; FIBRINOLYTIC AGENT; TETRAZOLE DERIVATIVE;

ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); FIBRINOLYTIC THERAPY; HEART FAILURE; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE PATIENT; AGED; COMPLICATION; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; BRAIN ISCHEMIA; DATABASES, FACTUAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; STROKE; TETRAZOLES;

EID: 84928243646     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.12.002     Document Type: Article

References (42)

1. S.T. Pendlebury, and P.M. Rothwell Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis Lancet Neurol 8 2009 1006 1018
2. M.G. Lansberg, M.J. O'Donnell, and P. Khatri Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines Chest 141 2012 e601S e636S
3. K.L. Furie, S.E. Kasner, and R.J. Adams Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 227 276
4. P.A. Howard Aspirin resistance Ann Pharmacother 36 2002 1620 1624
5. J. He, P.K. Whelton, and B. Vu Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials JAMA 280 1998 1930 1935
6. P.B. Gorelick, and S.M. Weisman Risk of hemorrhagic stroke with aspirin use: an update Stroke 36 2005 1801 1807
7. M.J. O'Donnell, G.J. Hankey, and J.W. Eikelboom Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review Stroke 39 2008 1638 1646
8. Committee CS A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie). Caprie steering committee Lancet 348 1996 1329 1339
9. D.L. Bhatt, K.A. Fox, and W. Hacke Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
10. H.C. Diener, J. Bogousslavsky, and L.M. Brass Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
11. T. Sudo, K. Tachibana, and K. Toga Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity Biochem Pharmacol 59 2000 347 356
12. J. Kambayashi, Y. Liu, and B. Sun Cilostazol as a unique antithrombotic agent Curr Pharm Des 9 2003 2289 2302
13. J.L. Anderson, J.L. Halperin, and N. Albert Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 1555 1570
14. H.B. Panchal, T. Shah, and P. Patel Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis J Cardiovasc Pharmacol Ther 18 2013 533 543
15. J. Sarris, and G.J. Byrne A systematic review of insomnia and complementary medicine Sleep Med Rev 15 2011 99 106
16. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
17. D. Moher, A. Liberati, and J. Tetzlaff Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
18. J.G.S. Higgins Cochrane handbook for systematic reviews of interventions version 5.1[updated march 2011] 2011 The Cochrane Collaboration [accessed December 2012] http://www.cochrane-handbook.org
19. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
20. P. Juni, D.G. Altman, and M. Egger Systematic reviews in health care: assessing the quality of controlled clinical trials BMJ 323 2001 42 46
21. M. Egger, G.D. Smith, and M. Schneider Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
22. S.U. Kwon, K.S. Hong, and D.W. Kang Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis Stroke 42 2011 2883 2890
23. Y. Shinohara, Y. Katayama, and S. Uchiyama Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial Lancet Neurol 9 2010 959 968
24. H. Shimizu, T. Tominaga, and A. Ogawa Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial J Stroke Cerebrovasc Dis 22 2013 449 456
25. Y.S. Lee, H.J. Bae, and D.W. Kang Cilostazol in acute ischemic stroke treatment (CAIST Trial): a randomized double-blind non-inferiority trial Cerebrovasc Dis 32 2011 65 71
26. S.U. Kwon, Y.J. Cho, and J.S. Koo Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis Stroke 36 2005 782 786
27. T. Nakamura, S. Tsuruta, and S. Uchiyama Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study J Neurol Sci 313 2012 22 26
28. J.J. Guo, E. Xu, and Q.Y. Lin Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke Neurosci Bull 25 2009 383 390
29. Y. Huang, Y. Cheng, and J. Wu Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study Lancet Neurol 7 2008 494 499
30. F. Gotoh, H. Tohgi, and S. Hirai Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction J Stroke Cerebrovasc Dis 9 2000 147 157
31. K. Nakamura, F. Ikomi, and T. Ohhashi Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles J Vasc Res 43 2006 86 94
32. H. Ito, K. Uehara, and Y. Matsumoto Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits PLoS One 7 2012 e39374
33. Y. Sugiura, T. Morikawa, and T. Takenouchi Cilostazol strengthens the endothelial barrier of postcapillary venules from the rat mesentery in situ Phlebology 29 2013 294 299
34. Y. Nonaka, K. Tsuruma, and M. Shimazawa Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage Neurosci Lett 452 2009 156 161
35. L.B. Goldstein, C.D. Bushnell, and R.J. Adams Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 517 584
36. J. Reid, M.J. MacLeod, and D. Williams Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units Scott Med J 50 2005 69 72
37. L.L. Yeo, P. Paliwal, and H.L. Teoh Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke JAMA Neurol 70 2013 353 358
38. S. Birk, C. Kruuse, and K.A. Petersen The headache-inducing effect of cilostazol in human volunteers Cephalalgia 26 2006 1304 1309
39. R.J. Malloy, A.O. Kanaan, and M. Silva Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis Clin Ther 35 2013 1490 1500.e7
40. J.J. Dinicolantonio, C.J. Lavie, and H. Fares Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke Am J Cardiol 112 2013 1230 1234
41. A.K. Kamal, I. Naqvi, and M.R. Husain Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin Cochrane Database Syst Rev 2011 CD008076
42. Y. Qian, and Q. Bi Systematic study of cilostazol on secondary stroke prevention: a meta-analysis Eur J Med Res 18 2013 53